These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
537 related items for PubMed ID: 28914107
1. Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae. Watkins RR, Deresinski S. Expert Rev Anti Infect Ther; 2017 Oct; 15(10):893-895. PubMed ID: 28914107 [No Abstract] [Full Text] [Related]
2. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options. Aslan AT, Akova M. Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185 [Abstract] [Full Text] [Related]
3. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis. Sfeir MM, Askin G, Christos P. Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138 [Abstract] [Full Text] [Related]
4. Carbapenemase-Producing Enterobacteriaceae Isolates from Edo State, Nigeria. Jesumirhewe C, Springer B, Lepuschitz S, Allerberger F, Ruppitsch W. Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607027 [No Abstract] [Full Text] [Related]
5. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects. Sheu CC, Lin SY, Chang YT, Lee CY, Chen YH, Hsueh PR. Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125 [Abstract] [Full Text] [Related]
12. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis? Stupica D, Lusa L, Klevišar MN, Terzić S, Pirš M, Premru MM, Strle F. Int J Antimicrob Agents; 2017 Oct 01; 50(4):564-571. PubMed ID: 28711676 [Abstract] [Full Text] [Related]
13. Mechanisms of carbapenem resistance among a collection of Enterobacteriaceae clinical isolates in a Texas city. Bennett JW, Mende K, Herrera ML, Yu X, Lewis JS, Wickes BL, Jorgensen JH, Murray CK. Diagn Microbiol Infect Dis; 2010 Apr 01; 66(4):445-8. PubMed ID: 20226336 [Abstract] [Full Text] [Related]
18. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria. D'Angelo RG, Johnson JK, Bork JT, Heil EL. Expert Opin Pharmacother; 2016 Dec 01; 17(7):953-67. PubMed ID: 26891857 [Abstract] [Full Text] [Related]
19. The rapid spread of carbapenem-resistant Enterobacteriaceae. Potter RF, D'Souza AW, Dantas G. Drug Resist Updat; 2016 Nov 01; 29():30-46. PubMed ID: 27912842 [Abstract] [Full Text] [Related]
20. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Peterson LR. Clin Microbiol Infect; 2008 Jan 01; 14 Suppl 1():181-4. PubMed ID: 18154544 [Abstract] [Full Text] [Related] Page: [Next] [New Search]